Late last year, the U.S. Food and Drug Administration (FDA) approved an at-home brain stimulation device developed by the ...

Earlier this week, the United States Food and Drug Administration (FDA) approved a human trial for a blueberry-sized brain ...

TRENTON, N.J. (AP) — The U.S. Food and Drug Administration has approved the first drug specifically developed for severe depression after childbirth. The agency on Tuesday approved Sage Therapeutics' ...

In April 2026, COMPASS Pathways announced that the FDA granted a rolling NDA review for its synthetic psilocybin therapy COMP360 in treatment-resistant depression and selected it for the ...

Add Yahoo as a preferred source to see more of our stories on Google. The Rejoyn app for major depression is designed to improve brain functioning. People in treatment for major depression now have ...

NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to help ...

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson‘s Caplyta as an add-on treatment for adults with major depressive disorder. Following the FDA’s Nov. 5 decision ...

The Food and Drug Administration (FDA) has approved a new smartphone app, Rejoyn, for the treatment of depression. The app was created by Otsuka Pharmaceutical Co. and Click Therapeutics, and it ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images. Major ...

The FDA has approved Transcranial Magnetic Stimulation (TMS), a non-drug, magnetic pulse device, for use in teens as young as 15 to treat severe depression. TMS is now an option for adolescents who ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a standalone ...